What is the value of AbbVie's acquisition of Apogee?

The deal is valued at $10.9 billion in cash.

Why did Apogee's stock rally 46%?

The stock surged after AbbVie announced the acquisition at a 46% premium over the previous closing price.

When is the AbbVie-Apogee deal expected to close?

The deal is expected to close in the second half of 2026.

What are AbbVie's motives for acquiring Apogee?

AbbVie aims to strengthen its oncology and rare disease pipeline and offset revenue losses from patent expirations.

AbbVie to Acquire Apogee for $10.9B, Boosting Oncology Pipeline

AbbVie (ABBV) announced it will acquire Apogee Therapeutics in an all-cash deal valued at $10.9 billion, causing Apogee shares to surge 46%. The acquisition is expected to close in the second half of 2026 and aims to bolster AbbVie's pipeline in oncology and rare diseases.

AbbVie (ABBV) announced today it will acquire Apogee Therapeutics in a $10.9 billion all-cash deal, according to reports. The news sent Apogee shares up 46% in pre-market trading, while AbbVie shares saw modest movement. The transaction is expected to close in the second half of 2026.

Deal Details

Item	Value
Deal Value	$10.9 billion cash
Premium	46% over Apogee's closing price prior to announcement
Payment Method	All cash
Expected Close	H2 2026

Rationale

AbbVie aims to strengthen its pipeline in oncology and rare diseases with this acquisition. Apogee has several promising drugs in late-stage development that could help offset revenue losses from upcoming patent expirations on some of AbbVie's key drugs.

Regulatory Challenges

The deal will likely face antitrust reviews in the U.S. and Europe. However, given the limited overlap in product portfolios, it is expected to pass without major hurdles.

Impact on Stocks

For AbbVie investors, the deal may increase short-term debt but offers long-term growth opportunities. Apogee investors received a significant premium but lose the chance for independent upside.

What This Means for Investors

AbbVie investors should monitor regulatory developments and the impact on cash flows. Apogee investors may seek alternative investment opportunities post-close.